NKTR
$75.06
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Recent News
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Mar 16, 2026
Companies In The News Are: ADBE, META, NKTR, ORKA.
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Nektar Therapeutics Q4 2025 Earnings Call Summary
Moby summary of Nektar Therapeutics's Q4 2025 earnings call